Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children <3 years of age

Journal of Infectious Diseases

Volumn 210, Issue 11, 2014, Pages 1800-1810

  Nolan, Terry ^a   Izurieta, Patricia ^e   Lee, Bee Wah ^f   Chan, Poh Chong ^g   Marshall, Helen ^b,c   Booy, Robert ^d   Drame, Mamadou ^h   Vaughn, David W ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e GSK   (Belgium)

^f MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Booster; Children; H5N1; Influenza; Pandemic

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CHILD; CHILD HEALTH; CLADISTICS; CLINICAL EFFECTIVENESS; COUGHING; DIARRHEA; DRUG EFFICACY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INFLUENZA A (H5N1); INFLUENZA A VIRUS (H5N1); INFLUENZA VACCINATION; INJECTION SITE SWELLING; IRRITABILITY; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RHINITIS; RHINOPHARYNGITIS; RHINORRHEA; SKIN REDNESS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS STRAIN; VOMITING; CLINICAL TRIAL; EPIDEMIOLOGY; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFLUENZA VIRUS A H5N1; INFLUENZA, HUMAN; SINGAPORE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; SINGAPORE; VACCINATION;

EID: 84922326721     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu359     Document Type: Article

References (36)

1. World Health Organization. H5N1 avian influenza: Timeline of major events 13 December 2011. Geneva: WHO, 2011. http://www.who.int/influenza/human-animal-interface/avian-influenza/H5N1-avian-influenza-update.pdf. Accessed 2 October 2013.
2. WHO. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to. http://www.who.int/influenza/human-animal-interface/H5N1-cumulative-table-archives/en/. Accessed 12 February 2014.
3. Update on human cases of influenza at the human-animal interface, 2012. Wkly Epidemiol Rec 2013; 88:137-44.
4. World Health Organization. WHO activities in avian influenza and pandemic influenza preparedness. http://www.who.int/influenza/resources/documents/WHO-CDS-EPR-GIP-2006-6.pdf. Accessed 1 April 2012.
5. Sellwood C, Asgari-Jirhandeh N, Salimee S. Bird flu: if or when? Planning for the next pandemic. Postgrad Med J 2007; 83:445-50.
6. H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure, 2013. http://www.gsk.com/media/press-releases/2013/h5n1-vaccine-approved-by-the-u-s-fda-as-pandemic-influenza-prep.html. Accessed 5 December 2013.
7. Viboud C, Boëlle P-Y, Cauchemez S, et al. Risk factors of influenza transmission in households. Br J Gen Pract J R Coll Gen Pract 2004; 54:684-9.
8. Glatman-Freedman A, Portelli I, Jacobs SK, et al. Attack rates assessment of the 2009 pandemic H1N1 influenza A in children and their contacts: a systematic review and meta-analysis. PLoS One 2012; 7:e50228.
9. Rümke HC, Bayas J-M, de Juanes J-R, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-88.
10. Gillard P, Caplanusi A, Knuf M, et al. An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respir Viruses 2013; 1:55-65.
11. Leroux-Roels I, Roman F, Forgus S, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57.
12. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644-53.
13. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:e1665.
14. Díez-Domingo J, Garcés-Sanchez M, Baldó J-M, et al. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J 2010; 29:e35-46.
15. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103: 163-71.
16. Kendal A, Pereira M, Skehel J. Hemagglutination inhibition. Concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: Centers for Disease Control and Prevention and Pan-American Health Organization, 1985.
17. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
18. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 2004; 103:91-5.
19. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103:133-8.
20. Beyer WE, Palache AM, Baljet M, Masurel N. Antibody induction by influenza vaccines in the elderly: a review of the literature. Vaccine 1989; 7:385-94.
21. A revised system of nomenclature for influenza viruses. Bull World Health Organ 1971; 45:119-24.
22. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649.
23. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7:e33536.
24. Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794.
25. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain J Neurol 2013; 136:2486-96.
26. Heier MS, Gautvik KM, Wannag E, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 2013; 14:867-71.
27. Szakács A, Darin N, Hallböök T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013; 80:1315-21.
28. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31:1246-54.
29. Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010 final report of National Narcolepsy Study Steering Committee, 2012. http://healthupdate.gov.ie/wp-content/uploads/2012/04/Final-Report-of-National-Narcolepsy-Study-Steering-Committee-latest1.pdf. Accessed 6 December 2013.
30. European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination. A multi-country European epidemiological investigation. Stockholm: ECDC, 2012.
31. Pitkänen M. Increased risk of narcolepsy observed also among adults vaccinated with Pandemrix in Finland, 2013. http://www.thl.fi/en-US/web/en/pressrelease?id=33516. Accessed 31 July 2013.
32. Registry study confirms increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents and shows an increased risk in young adults. Uppsala, Sweden: Medical Products Agency, 2013. http://www.lakemedelsverket.se/english/All-news/NYHETER-2013/Registry-study-confirms-increased-risk-of-narcolepsy-after-vaccination-with-Pandemrix-in-children-and-adolescents-and-shows-an-increased-risk-in-young-adults/. Accessed 31 July 2013.
33. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011; 70:410-7.
34. De la Herrán-Arita AK, Kornum BR, Mahlios J, et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 2013; 5:216ra176.
35. Risi G, Frenette L, Langley JM, et al. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine 2011; 29:6408-18.
36. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. Wkly Epidemiol Rec 2011; 86:469-80.